Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Treatment Satisfaction and Preference for Sumavel DosePro in the Treatment of Migraine

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* History of 2 to 6 migraine headaches per month~* Migraines should have been present for at least 1 year with age at onset of migraine less than 50 years~* History of 24 hours of freedom between migraine attacks~* Current users of triptan medications~* Able to distinguish interval or other non-migrainous headaches from typical migraine~* General good health~Exclusion Criteria:~* History or symptoms, or signs of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes~* Significant underlying cardiovascular diseases including uncontrolled hypertension~* Hemiplegic or basilar migraine~* History or diagnosis of severe hepatic or renal impairment~* History of epilepsy or seizure or other serious neurologic condition~* History of allergy, anaphylaxis, or hypersensitivity to sumatriptan or any of its components or similar drugs including sulphonamides~* History of scleroderma (systemic sclerosis)~* Pregnant or breastfeeding~* Use of contraindicated prescription medications, monoamine oxidase inhibitors (MAO-A), selective serotonin reuptake inhibitors, or lithium agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Sumavel(R) DosePro(R) (Type: OTHER): Single arm study (Sumavel DosePro)

Based on this trial design, predict the completion outcome and termination type (if applicable).